Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (NASDAQ: RARE) reported an inducement grant under Nasdaq Listing Rule 5635(c)(4) consisting of 36,447 restricted stock units awarded to 12 newly hired non-executive officers with a grant date of April 16, 2026.

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) reported an inducement grant under Nasdaq Listing Rule 5635(c)(4) consisting of 36,447 restricted stock units awarded to 12 newly hired non-executive officers with a grant date of April 16, 2026.

The RSUs vest over four years with 25% vesting on each anniversary, conditional on continued employment.

Argus Apr 27 session

-0.46% close to close Open Argus

Details

News Market Reaction – RARE

On Apr 27, the first trading day after this news, RARE closed 0.46% below the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Key Figures

Current price: $24.10 Inducement RSUs granted: 36,447 RSUs New hires: 12 employees +1 more

Current price

$24.10

Pre-news trading level on publication date

Inducement RSUs granted

36,447 RSUs

Restricted stock units granted to new non-executive officers

New hires

12 employees

Non-executive officers receiving inducement RSU awards

Vesting schedule

25% per year over 4 years

RSUs vest annually on each grant date anniversary

Historical Context

5 past events · Latest: Apr 02

5 events

1. Apr 02

   BLA resubmission accepted

   24h Move

   +4.8%

   FDA acceptance of UX111 BLA resubmission with set PDUFA action date.

2. Mar 30

   IND clearance

   24h Move

   -0.4%

   FDA clears IND for UX016 enabling Phase 1/2 study in GNE myopathy.

3. Mar 27

   Class action notice

   24h Move

   -0.4%

   Notice of class action lawsuit application deadline for shareholders.

4. Mar 20

   Inducement RSU grant

   24h Move

   +2.0%

   Disclosure of 10,839 RSUs granted to two newly hired officers.

5. Mar 12

   Phase 3 data update

   24h Move

   -2.3%

   Positive 36-week Phase 3 DTX301 data with significant ammonia reduction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), employment inducement plan

3 terms

restricted stock units financial

"reported the grant of 36,447 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

employment inducement plan financial

"granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2026"

An employment inducement plan is a package of pay, bonuses or stock-based awards offered to a new hire to persuade them to join a company, similar to a signing bonus or welcome offer. Investors care because these awards can increase payroll costs and dilute existing shares, while also signaling how much the company is spending to attract talent and align that new hire’s interests with shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 36,447 restricted stock units of the company’s common stock to 12 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of April 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ultragenyx announce about the April 16, 2026 RSU grant (RARE)?

The company granted 36,447 restricted stock units to 12 new non-executive officers. According to the company, the awards were approved by the compensation committee and issued under the Ultragenyx Employment Inducement Plan as an inducement under Nasdaq Rule 5635(c)(4).

How do the Ultragenyx (RARE) RSUs vest and when are vesting dates?

The RSUs vest over four years with 25% vesting each anniversary. According to the company, vesting is contingent on the employee being continuously employed on each anniversary of the April 16, 2026 grant date.

Who received the inducement awards from Ultragenyx (RARE) and under what plan?

Twelve newly hired non-executive officers received the awards under the Ultragenyx Employment Inducement Plan. According to the company, the awards were intended as inducements to enter employment and were approved by the compensation committee.

Why did Ultragenyx (RARE) use Nasdaq Listing Rule 5635(c)(4) for the grant?

The company used Rule 5635(c)(4) to classify the awards as employment inducements for new hires. According to the company, this treatment allowed the grants to be issued specifically as material inducements for newly hired non-executive officers.

Does the Ultragenyx RSU grant (RARE) immediately affect shareholder dilution?

The announcement details the number of RSUs granted but does not quantify immediate dilution. According to the company, 36,447 RSUs were granted; any dilution effect depends on future settlement of those units and total shares outstanding.